Forest Labs
Executive Summary
Reports that interim analysis of data from Phase III studies with Synapton (physostigmine controlled release) shows efficacy "significantly different" from Warner-Lambert's Cognex. In the Aug. 8 press release, Forest also said that Synapton lacks the liver toxicity and other side effects normally associated with cholinesterase inhibitors.